bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-71-5004

Order Name:
PGx panel – myDNA Medication test **

 
Useful For:

Predict drug response for improved patient treatment and better healthcare quality

Suitable for:

  1. People who take drugs or are planning to start taking drugs
  2. People who have underlying disease and take many drugs e.g. children, elderly
  3. People who want to know the prediction of drug response for planning drug treatment in the future
 
Methodology:

Genotyping

 
Test List In Profile:
CYP2D6 
CYP2C19
CYP2C9
VKORC1
CYP1A2
CYP3A4
CYP3A5
SLCO1B1
OPRM1
 
AliasesName:
Pharmacogenomics test 9 drugs
gene tests related to drug
Sensitivity to warfarin, opioid, statins
CYP2D6 
CYP2C19
CYP2C9
VKORC1
CYP1A2
CYP3A4
CYP3A5
SLCO1B1
OPRM1
 
 
 
Test Code:
090-71-5004

Order Name:
PGx panel – myDNA Medication test **

 
Patient Preparation:

Do not eat, drink (except for water), smoke, brush your teeth or chew gum for 1 hour before collecting the buccal sample

 
Collection Specimen Or Container:
Buccal Swab - MyDNA Medication collection kit
 
Specimen Testing Type:
Buccal Swab  (Extracted DNA from cheek cells)
 
Sub Mission Container:
Original container
 
Rejection Criteria:
In the event where a sample was not adequately collected, damaged upon arrival to the lab or forms were not filled in their entirety you will be resupplied with a new myDNA test kit for sample recollection.
 
Specimen Stabillity:
As long as the sample/tube is kept at room temperature, it will be usable for 3 months.
 
 
 
Test Code:
090-71-5004

Order Name:
PGx panel – myDNA Medication test **

 
Method detail:

MyDNA Life offers pharmacogenomic testing through two NATA accredited laboratories: GenSeq Laboratories (NATA accredited lab No 20082) and Australian Clinical Labs (NATA accredited lab No 3427).

  1. GenSeq Laboratories: DNA is extracted and SNP genotyping is performed using open array technology (Life Technologies QuantStudio 12K). CYP2D6 copy number is established by real time PCR (QuantStudio 6), allowing for quantification of up to 4 copies.
  2. Australian Clinical Labs: DNA is extracted and SNP genotyping is performed using the Agena MassArray platform. CYP2D6 copy number is confirmed by long-range PCR. There are usually only 2 copies for the CYP2D6 gene when it is duplicated, however, there may be more than 2 copies in some cases. Current technical limitations of the test do not allow measurement of the exact gene copy number.
 
Schedule:
N/A **Sent Out to myDNA Life, Australia
 
Turnaround Time:
Reported within 20-25 days (exception for official holidays)
 
Performing Location:
myDNA Life, Australia
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-71-5004

Order Name:
PGx panel – myDNA Medication test **

 
 
Clinical Information:
The myDNA Medication test examines the important DNA variants that affect drug response for over 80 medications used in clinical practice. These include certain antidepressants, antipsychotics, analgesics, anticoagulants, antiplatelets and proton pump inhibitors. Current TGA regulations prohibit the myDNA website from listing individual medications by name, but a list of the main medications that can be tested for is available for doctors and pharmacists. 

Test 9 genes: CYP2D6, CYP2C19, CYP2C9, VKORC1, CYP1A2, CYP3A4, CYP3A5, SLCO1B1, and OPRM1
 
 
Interpretation:
Once testing is completed, the result with clinical interpretation report which is prepared by a team comprising physicians, pharmacists and molecular geneticists will be provided. Interpretation is based on the primary pharmacogenomic literature with reference to the published clinical recommendations of Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG).

Post-counselling service by expert pharmacogeneticians is provided.


Test Limitaion:
The myDNA medication test detects common variants in 9 genes (6 genes encoding CYP450 drug metabolising enzymes, VKORC1, encoding a protein that partially determines sensitivity to warfarin, OPRM1 encoding the mu receptor which has been associated with opioid sensitivity, and SLCO1B1, encoding a drug transporter important for statins). The genes tested in the myDNA medication test have clinically significant associations which have been documented in the peer-reviewed literature and, for some have associated published clinical practice guidelines.

There are important myDNA test limitations to consider:

  1. The test only provides information about medications for which one or more of the nine genes are known to influence medication concentration or response. Therefore, the test cannot determine how individuals respond to all medications in clinical use.
  2. Response to medications is complex and often incompletely understood. The myDNA medication test only looks at one aspect which may affect medication response (i.e. changes in drug concentration due to genetic variation) and this should be considered when interpreting the test. Of note, a “normal” result does not predict that the patient will always respond to a medication and not experience any side effects, and allergic reactions cannot be detected by this genetic test.
  3. The test does not detect all known variants in the genes tested. Only common variants are tested that are present in Caucasian, African and Asian backgrounds. If an individual carries a rare variant or a variant mostly found in other ethnicities, then this variant will not be detected, the allele will be classified as the default or wild type (e.g. *1) and the phenotype may be inaccurate. Only testing the common variants is the practice of most screening molecular genetic testing laboratories around the world.

1. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215-23.

 
Clinical Reference:
www.mydna.life/pharmacogenomic-testing (Retrieved: 16 May 2020)